Research & Development

EnGeneIC begins Phase I trial of nanocellular vaccine for Covid-19

EnGeneIC has started dosing in Phase I clinical trial of the world’s first nanocellular technology-based anti-Covid-19 vaccine in healthy adults.

Adaptimmune and Genentech partner on allogeneic cell therapies

Adaptimmune Therapeutics has signed a strategic partnership and licence agreement with Roche Group member, Genentech, for the development and commercialisation of allogeneic cell therapies across several cancer indications.

Roche to withdraw US accelerated approval for Tecentriq to treat breast cancer

Roche has decided to voluntarily withdraw the US accelerated approval for Tecentriq (atezolizumab) in combination with Abraxane (nab-paclitaxel) to treat patients with PD-L1-positive metastatic triple-negative breast cancer (mTNBC).

Lilly and Lycia sign agreement for LYTAC degraders development

Eli Lilly and Company and Lycia Therapeutics have signed a multi-year collaboration and licensing agreement for the discovery and development of novel lysosomal targeting chimera (LYTAC) degraders.

Roche signs strategic collaboration and licence agreement with Roche

Shape Therapeutics has entered into a multi-target strategic collaboration and licence agreement with Roche to develop gene therapy for particular targets in the areas of Alzheimer’s disease, Parkinson’s disease, and rare diseases.

CM Life Sciences II, SomaLogic and Twist Bioscience partner for novel antibodies

CM Life Sciences II and SomaLogic have collaborated with Twist Bioscience to discover novel therapeutic targets and antibodies.

Aurinia buys two pipeline assets to boost autoimmune and kidney diseases portfolio

Aurinia Pharmaceuticals has bought two new pipeline assets to boost its rare autoimmune and kidney-related disease portfolio.

Gritstone signs funding deal with CEPI to develop Covid-19 vaccine programme

Gritstone bio and the Coalition for Epidemic Preparedness Innovations (CEPI) have signed a funding agreement to advance the development of the former’s second-generation Covid-19 vaccine programme (CORAL) against SARS-CoV-2 variants.

GentiBio raises $157m through Series A funding round

Biotherapeutics company GentiBio has raised $157m through a Series A funding round, which was led by Matrix Capital Management.